MMHP
VKTX icon

Murphy Middleton Hinkle & Parker’s Viking Therapeutics VKTX Stock Holding History

Murphy Middleton Hinkle & Parker’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,706
Closed -$820K – 217
2025
Q4 		$820K Buy
+1,706
New +$60.4K 0.4% 70

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Murphy Middleton Hinkle & Parker's VKTX Position: Q1 2026 in Review

Murphy Middleton Hinkle & Parker sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 1,706 shares — an estimated $820K sold.

Murphy Middleton Hinkle & Parker first reported a position in VKTX in Q4 2025 and held it in 1 quarter. The position peaked at $820K in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Murphy Middleton Hinkle & Parker reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Murphy Middleton Hinkle & Parker sold 1,706 Viking Therapeutics shares in Q1 2026, an estimated $820K.
  • Murphy Middleton Hinkle & Parker first reported a position in Viking Therapeutics in Q4 2025 and held it in 1 quarter.
  • Murphy Middleton Hinkle & Parker's Viking Therapeutics position peaked at $820K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Murphy Middleton Hinkle & Parker's 13F filing for Q1 2026, filed 15 Apr 2026.